Capricor Therapeutics, Inc.（CAPR）股票分析CAPRCapricor Therapeutics, Inc.

Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Capricor Therapeutics Inc is not a good buy right now due to its current price of $6.71, which is significantly below the analyst price target of $21 from B. Riley, indicating potential upside. However, the stock has a very low RSI of 32.184, suggesting it is oversold, but the negative sentiment surrounding the FDA review delay and a projected 8% drop in stock price makes it risky. The main risk is the company's ongoing losses, with a net income of -40,733,654 USD for Q2 2026, which raises concerns about its financial health.

1 analysts cover CAPR: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 51.57.